Early detection of lung cancer: Role of biomarkers

European Respiratory Journal, Supplement

Volumn 21, Issue 39, 2003, Pages

  Brambilla, C ^a,b   Fievet, F ^a,b   Jeanmart, M ^a,b   De Fraipont, F ^a,b   Lantuejoul, S ^a,b   Frappat, V ^a,b   Ferretti, G ^a,b   Brichon, P Y ^a,b   Moro Sibilot, D ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Biomarkers; Early detection; Fluorescent bronchoscopy; Lung cancer; Methylation; Preneoplasia

Indexed keywords

BIOLOGICAL MARKER; CADHERIN; CADHERIN H; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; FRAGILE HISTIDINE TRIAD PROTEIN; METALLOPROTEINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; RETINOIC ACID RECEPTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; TUMOR MARKER;

APOPTOSIS; BRONCHOSCOPY; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL REGENERATION; CONFERENCE PAPER; DIAGNOSTIC VALUE; DNA METHYLATION; DNA REPAIR; EARLY DIAGNOSIS; GENE EXPRESSION; GENE MUTATION; HETEROZYGOSITY LOSS; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG CARCINOGENESIS; MOLECULAR GENETICS; PRECANCER; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; SPUTUM CYTODIAGNOSIS; TUMOR SUPPRESSOR GENE; BRONCHUS TUMOR; CYTOLOGY; GENETICS; HUMAN; LUNG TUMOR; METHODOLOGY; MOLECULAR BIOLOGY; MUTATION; REVIEW; SPUTUM;

BRONCHIAL NEOPLASMS; BRONCHOSCOPY; DNA, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MOLECULAR BIOLOGY; MUTATION; SPUTUM; TOMOGRAPHY, SPIRAL COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 0037241268     PISSN: 09041850     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (93)

1. Schottenfeld D. Etiology and epidemiology of lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, eds. Lung Cancer: Principles and practice. Philadelphia, USA, Lippincott Williams and Wilkins, 2000; pp. 367-388.
2. Boyle P, Gandini S, Gray N. Epidemiology of lung cancer: a century of great success and ignominious failure. In: Hansen HH, ed. Textbook of lung cancer. London, UK, Martin Dunitz, 2000; pp. 13-25.
3. Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990. Eur J Cancer 1997; 33: 1075-1107.
4. Minna JD, Sekido Y, Fong K, Gazdar AF. Molecular biology of lung cancer. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology, 5th edition. Philadelphia, Lippincott, 1997; 30.I, 849-857.
5. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
6. Hunter T. Oncoprotein networks. Cell 1997; 88: 333-346.
7. Michalides RJA. Deregulation of the cell cycle in lung cancer. In: Brambilla E, Brambilla C, eds. Fundamental biology and clinical management. M. Dekker New-York, Basel, 1998; pp. 211-225.
8. Kishimoto Y, Sugio K, Hung JY, et al. Allele specific loss in chomosome 9p loci in preneoplastic lesions accompanying non small cell lung cancers. J Natl Cancer Inst 1995; 87: 1224-1229.
9. Chung GTY, Sundaresan V, Hasleton P, Rudd R, Taylor R, Rabbits P. Sequential molecular genetic changes in lung cancer development. Oncogene 1995; 11: 2591-2598.
10. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lung of current and former smokers. J Nat Cancer Inst 1997; 89: 857-862.
11. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Nat Cancer Inst 1997; 89: 1366-1373.
12. Auerbach O, Gere B, Forman JB, et al. Changes in bronchial epithelium in relation to smoking and cancer of the lung. N Engl J Med 1957; 256: 97-104.
13. Travis WD, Colby TB, Corrin B, Shimosato Y, Brambilla E. Histological typing of tumours of lung and pleura. In: Sobin LH, ed. World Health Organization International Classification of Tumours, 3rd edition. New York, Springer-Verlag, 1999; p. 245.
14. Lam S, Kennedy T, Unger M, et al. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscope. Chest 1998; 113: 696-702.
15. Band P, Feldstein M, Saccomanno G. Reversibility of bronchial marked atypia: implication for chemoprevention. Cancer Detect Treatment 1986; 9: 157-160.
16. Venman BJW, van Boxem TJM, Smit EF, Postmus PE, Sutedja TG. Outcome of bronchial carcinoma in situ. Chest 2000; 117: 1572-1576.
17. Bota S, Auliac JB, Paris C, et al. Follow-up of bronchial precancerous lesions and carcinoma in situ using fluorescence endoscopy. Am J Respir Crit Care Med 2001; 164: 1688-1693.
18. Wistuba II, Lam S, Behrens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Nat Cancer Inst 1997; 89: 1366-1373.
19. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lung of current and former smokers. J Nat Cancer Inst 1997; 89: 857-862.
20. Wistuba II, Behrens C, Milchgrub S, et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 1999; 18: 643-650.
21. Westra WH, Baas IO, Hruban RH. Atypical alveolar hyperplasias (AAHs) of the lung frequently harbor K-ras mutations: evidence to implicate AAH as the precursor lesion of lung adenocarcinoma. Mod Pathol 1996; 23: 164-167.
22. Kerr KM, Cary FA, King G, Lamb D. Atypical adenomatous hyperplasia: Relationship with pulmonary adenocarcinoma, p53, and c-erB-2 expression. J Pathol 1994; 174: 249-256.
23. Sozzi G. Deletions of the short arm of chromosome 3 and the FHIT gene in lung cancer. In: Brambilla E, Brambilla C, eds. Fundamental biology and clinical management. M. Dekker New-York, Basel, 1998; pp. 157-171.
24. Zhou W, Goodman SN, Galizia G, et al. Counting alleles to predict recurrence of early stage resected colo-rectal cancers. Lancet 2002; 359: 219-225.
25. INK4A inactivation in non small-cell lung cancers. Oncogene 1998; 16: 497-505.
26. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998; 95: 11891-11896.
27. Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res 2001; 61: 249-255.
28. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60: 5954-5958.
29. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59: 67-70.
30. Kurakawa E, Shimamoto T, Utsumi K, Hirano T, Kato H, Ohyashiki K. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer. Int J Oncol 2001; 19: 277-281.
31. INK4b methylation status. Oncogene 2001; 20: 6587-6596.
32. Virmani AK, Rathi A, Zochbauer-Muller S, et al. Promoter methylation and silencing of the retinoic acid receptor-beta gene in lung carcinomas. J Natl Cancer Inst 2000; 92: 1303-1307.
33. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77: 82-37.
34. Brambilla E, Gazzeri S, Moro Sibilot D, et al. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 1993; 143: 199-210.
35. Brambilla E, Gazzeri S. P53 pathway and lung cancer. In: Brambilla E, Brambilla C, eds. Fundamental biology and clinical management. M Dekker NewYork, Basel, 1998; pp. 173-190.
36. Rusch V, Klimstra D, Venkatraman E, Pisters PWT, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor α is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997; 3: 515-522.
37. Schneider PM, Hung MC, Chiocca SM, et al. Differential expression of the c-erbB-2 gene in human small cell an non-small cell lung cancer. Cancer Res 1989; 49: 4968-4971.
38. Liu C, Tsao MS. In vitro and in vivo expressions of transforming growth factor and tyrosine kinase receptors in human non-small-cell lung carcinomas. Am J Pathol 1993; 142: 1155-1162.
39. Kern J, Schwartz DA, Nordberg JE, et al. p185neu expression in human adenocarcinomas predicts shortened survival. Cancer Res 1990; 50: 5184-5191.
40. Jacobson DR. Ras mutations in lung cancer. In: Brambilla E, Brambilla C, eds. Fundamental biology and clinical management. M. Dekker New-York, Basel, 1998; pp. 139-156.
41. Rodenhuis S, Slebos RJC. Significance of ras oncogene activation in human lung cancer. Cancer Res 1992; 52: 2665-2669.
42. Slebos RJC, Kibbelaar RE, Dalesio MDO. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Eng J Med 1990; 323: 561-565.
43. Suggio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T. Ras gene mutation as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 1992; 52: 2903-2906.
44. Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993; 8: 2407-2412.
45. Rosell R, Li S, Anton A, et al. Prognostic value of K-ras genotypes in patients with advanced non-small cell lung cancer receiving carboplatin with either intravenous or chronic oral dose etoposide. Int J Oncol 1994; 5: 169-176.
46. Keohavong P, Demichele MAA, Malacrinos AC, Landreneau RJ, Weyant RJ, Siegfried RJW. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 1996; 2: 411-418.
47. Urban T, Ricci S, Lacave R, et al. Codon 12 ki-ras mutation in non-small cell lung cancer: comparative evaluation in tumoral and non-tumoral lung. Br J Cancer 1996; 74: 1051-1055.
48. Mills NE, Fishman CL, Scholes J, et al. Detection of K-ras oncogene mutations in bronchioalveolar lavage fluid for lung cancer diagnosis. J Natl Cancer Inst 1995; 87: 1056-1060.
49. Lane D. P53, guardian of the genome. Nature 1992; 358: 15-16.
50. Levine AJ. P53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
51. Gazzeri S, Brambilla E, Caron de Fromentel C, et al. p53 genetic abnormalities and myc activation in human lung carcinomas. Int J Cancer 1994; 58: 24-32.
52. Greenblatt MS, Bennet WP, Hollstein M, Harris CC. Mutations in the P53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
53. Denissenko MF, Pao A, Tang MS, Pfeifer GP. Preferential formation of benzo(a)pyrene adducts at lung cancer mutational hotspots in P53. Science 1996; 274: 430-432.
54. Brambilla E, Gazzeri S, Lantuejoul S, et al. P53 mutant immunophenotype and deregulation of P53 transcription pathway (Bcl2, Bax, Waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 1998; 4: 1609-1618.
55. Pastorino U, Andreola S, Tagliabue E, et al. Immuno-cytochemical markers in stage I lung cancer (NSCLC): relevance to prognosis. J Clin Oncol 1997; 15: 2858-2865.
56. Cai DW, Mukhopakhyay T, Liu Y, Fujiwara T, Roth JA. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Human Gene Therapy 1993; 4: 617-624.
57. Takahashi T, Carbone D, Takahashi T, et al. Wildtype but not mutant p53 suppresses the growth of human lung cancer cells bearing multiples genetic lesions. Cancer Res 1992; 52: 2340-2343.
58. Brambilla E, Brambilla C. P53 and lung cancer. Path Biol 1997; 45: 852-863.
59. Boers JE, Ten-Velde GPM, Thunnissen FBJM. P53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma. Am J Respir Crit Care Med 1996; 153: 411-416.
60. Ponticiello A, Barra E, Giani E, Bocchino M, Sanduzzi A. P53 immunohistochemistry can identify bronchial dysplastic lesions proceeding to lung cancer: a prospective study. Eur Respir J 2000; 15: 547-552.
61. Wu X, Bayle JH, Olson D, Levine AJ. The P53-mdm2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126-1332.
62. Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein mdm2. Nature 1996; 372: 694-698.
63. Prives C, Hall PA. The P53 pathway. J Pathol 1999; 187: 112-126.
64. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323-330.
65. Gazzeri S, Gouyer V. Inactivation of RB gene and pRB function in lung cancer. In: Brambilla E, Brambilla C, eds. Fundamental biology and clinical management. M. Dekker New-York, Basel, 1998; pp. 191-209.
66. Gouyer V, Gazzeri S, Brambilla E, et al. Loss of heterozygosity at the RB locus in primary malignant neuroendocrine lung carcinomas. Int J Cancer 1994; 58: 818-824.
67. INK4 expression in resected non small cell lung tumors. Cancer Res 1996; 56: 3415-3420.
68. INK4, Cyclin D1 expressions in non small cell lung carcinoma and their clinical significance. J Pathol 1999; 188: 351-360.
69. INK4-Cyclin D1) in preinvasive bronchial lesions. Clin Cancer Res 1999; 5: 243-250.
70. ARF. Cell 1997; 91: 649-659.
71. INK4 gene is frequently lost in small cell lung tumors. Cancer Res 1998; 58: 3926-3931.
72. Brambilla E, Negoescu A, Gazzeri S, et al. Apoptosis-related factors P53, Bcl2, and Bax in neuroendocrine lung tumors. Am J Pathol 1996; 149: 1941-1952.
73. 2 protein in nonsmall-cell lung carcinoma. N Engl J Medicine 1993; 329: 690-694.
74. 2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer 1995; 71: 1003-1007.
75. Sozzi G, Pastorino U, Moiraghi L, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998; 58: 5032-5037.
76. Harley CB. Telomere loss: mitotic clock or genetic time bomb? Mut Res 1991; 256: 271-282.
77. Rathi A, Kazuo Y, Onuki N, Virmani A, Gazdar AF. Telomerase and lung cancer. In: Brambilla E, Brambilla C, eds. Fundamental biology and clinical management. M. Dekker New-York, Basel, 1998; pp. 269-277.
78. Hiyama K, Hiyama E, Ishioka S, et al. Telomerase activity in small cell and non small cell lung cancers. J Natl Cancer Inst 1995; 87: 895-902.
79. Yashima K, Litzky LA, Kaiser L, et al. Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res 1997; 57: 2373-2377.
80. Field JK, Brambilla C, Hirsch FR, et al. Molecular biomarkers workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations. Lung Cancer 2001; 31: 339-345.
81. INKa promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J Clin Oncol 2000; 18: 3221-3229.
82. Field JK, Liloglou T, Xinarianos G, et al. Genetic alterations in bronchial lavage as a potential marker for individuals with a high risk of developing lung cancer. Cancer Res 1999; 59: 2690-2695.
83. Powell CA, Klares S, O'Connor G, Brody JS. Loss of heterozygosity in epithelial cells obtained by bronchial brushing: clinical utility in lung cancer. Clin Cancer Res 1999; 5: 2025-2034.
84. Mao L, Hruban RH, Boyle JO, Tockman M, Sidransky D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994; 54: 1634-1637.
85. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977; 37: 646-650.
86. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M. Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989; 46: 318-322.
87. Henschke C, McCauley D, Yankelevitz D, et al. Early lung cancer action project: overall design and findings from baseline screening. Lancet 1999; 354: 99-105.
88. Palcic B, Lam S, Hung J, MacAulay C. Detection and localization of early lung cancer by imaging techniques. Chest 1991; 99: 742-743.
89. Moro Sibilot D, Jeanmart M, Lantuejoul S, et al. Cigarette smoking, preinvasive bronchial lesions and autofluorescence bronchoscopy. Chest 2002; 122: 1902-1908.
90. Deygas N, Froudarakis M, Ozenne G, Vergnon JM. Cryotherapy in early superficial bronchogenic carcinoma. Chest 2001; 120: 26-31.
91. Hirsch FR, Gazdar AF, Gabrielson E, Lam S, Franklin WA. A histopathologic evaluation of premalignant and early malignant bronchial lesions: an interactive program based on internet digital images to improve WHO criteria for early diagnosis of lung cancer and for monitoring chemoprevention studies - a SPORE collaborative project. Lung Cancer 2000; 29: 211.
92. Nicholson AG, Perry LJ, Cury PM, et al. Reproducibility of the WHO/IASLC grading system for preinvasive squamous lesions of the bronchus: a study of interobserver and intra-observer variation. Histopathology 2001; 38: 202-208.
93. Hirsch FR, Prindiville SA, Miller YE, et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst 2001; 93: 1385-1391.